Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Evaxion Biotech ( (EVAX) ) has issued an update.
On October 17, 2025, Evaxion Biotech announced impressive results from a phase 2 trial of its AI-designed personalized cancer vaccine, EVX-01, for advanced melanoma. The trial demonstrated a 75% Objective Response Rate, with 12 out of 16 patients showing clinical responses, and 92% of patients still responding after 24 months. The data, presented at the ESMO Congress, highlights the vaccine’s potential as a new treatment option and underscores the precision of Evaxion’s AI-Immunology platform in identifying neoantigens. The company plans further clinical development in partnership, marking a significant milestone in personalized immunotherapy.
The most recent analyst rating on (EVAX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
Evaxion Biotech’s overall score is driven by its financial challenges, despite strong revenue growth and positive developments in R&D and partnerships. The technical analysis suggests neutral momentum, while valuation remains unattractive due to ongoing losses. The earnings call provided some optimism with financial stability and strategic progress, but regulatory and market challenges remain significant risks.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion is a pioneering TechBio company based in Denmark, specializing in developing AI-Immunology powered vaccines. The company focuses on creating novel immunotherapies for cancer, bacterial diseases, and viral infections using its proprietary AI platform. Evaxion has developed a clinical-stage oncology pipeline of personalized vaccines and a preclinical infectious disease pipeline addressing high unmet medical needs.
Average Trading Volume: 1,528,374
Technical Sentiment Signal: Hold
Current Market Cap: $60.64M
See more insights into EVAX stock on TipRanks’ Stock Analysis page.